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INTRODUCTION
Acetaminophen (APAP; 4'-hydroxyacetanilide) is a widely used over-the-counter analgesic and antipyretic in the United States. When used at recommended therapeutic doses, APAP is rarely associated with liver injury. Unfortunately, APAP can cause fatal acute liver failure when therapeutic doses are exceeded. This can occur when people purposely take an overdose or when people accidentally consume multiple products containing APAP. Due to this concern, a recent FDA Advisory Panel recommended lowering the maximum therapeutic dose of APAP (US-FDA, 2009 ) and this was followed by a Federal Register notice lowering the maximum APAP dose in prescription products (US-FDA, 2011 ).
Due to the concern over APAP-induced liver injury, a tremendous amount of research has been conducted to understand the mechanisms behind the pathogenesis. The least controversial and most critical step is the metabolism of APAP. At therapeutic doses, APAP is predominantly metabolized by the Phase II metabolic pathways of glucuronidation and sulfation. A small portion of APAP is metabolized by the Phase I cytochrome P450 metabolic pathway to the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is subsequently detoxified by conjugation with glutathione (GSH) (Bessems and Vermeulen, 2001; Hinson et al., 2010) . In overdose situations, the glucuronidation and sulfation pathways are overwhelmed and a larger portion of APAP is metabolized through the Phase I pathway. GSH levels are limited and once depleted below a critical level, NAPQI is free to react with cellular macromolecules.
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JPET Fast Forward. Published on November 1, 2011 as DOI: 10.1124/jpet.111.187948 at ASPET Journals on July 6, 2017 jpet.aspetjournals.org Downloaded from JPET #187948 5 After formation of significant quantities of NAPQI, the subsequent pathways leading to cellular injury have been extensively investigated but their contribution to the actual pathogenesis are more tentative (Jaeschke, 2005; Hinson et al., 2010) . Based on the weight of evidence, APAP binds to various proteins and disrupts their function, leading to altered cellular function. However, there are likely to be other direct or indirect effects of NAPQI leading to cell death, such as alteration of cellular redox status or disruption of signaling pathways. Despite the wide array of cellular pathways that have been shown to play a role in APAP-induced hepatotoxicity, it is clear that disruption of mitochondrial function is one of the key outcomes (Masubuchi et al., 2005; Hanawa et al., 2008; Burke et al., 2010) . After covalent binding and GSH depletion occur, APAP induces the mitochondrial permeability transition (MPT), which allows the leakage of mitochondrial constituents into the cytosol. Following activation of the MPT, mitochondria swell, lose membrane potential, and exhibit decreased oxidative phosphorylation with subsequent ATP depletion and necrotic cell death.
Although these are the key events that have been elucidated to date, there are likely other unidentified factors that play a role in the molecular pathogenesis. Given the significant GSH depletion that occurs after APAP overdose, it is likely that the dramatically altered redox status plays both direct and indirect roles in the pathogenesis. One such potential effect is a change in protein glutathionylation and subsequent altered protein function.
Glutathionylation involves the addition of GSH to free sulfhydryl groups on proteins through a disulfide bond. The process is reversible so glutathionylation can change dynamically with changes in redox status, such as increased glutathionylation noted after This article has not been copyedited and formatted. The final version may differ from this version. microscopy by a board-certified veterinary pathologist. Lesions were scored on a 5-point scale (0-normal, 1-minimal, 2-mild, 3-moderate, 4-marked).
GSH/GSSG Analysis.
Immediately after euthanasia, the liver was quickly removed from the animal, flash frozen in an isopentane/dry ice slurry, and then stored at -80°C until analysis. A portion (~50 mg) was homogenized in 500 µL cold methanol (stored at -20 ºC). Labeled internal
N-GSH (Cambridge Isotopes, Andover, MA) was added to the homogenized sample, centrifuged for 15 minutes at 13,000 x g and 4 ºC then the supernatant was transferred and concentrated by using a Savant SpeedVac Plus SC 110A vacuum concentrator (Thermo Scientific, Asheville, NC). Dried samples were reconstituted in 500 µL of 5% acetonitrile, vortexed and then centrifuged for 15 minutes at 13,000 x g and 4ºC. GSH/GSSG was separated on a Waters (Milford, MA) BEH reverse-phase C18 column (2.1 x 100mm, 1.7 µm particle size) with mobile phase A = 0.1 % formic acid in water and mobile phase B = 0.1 % formic acid in acetonitrile. Western Blots.
The protein S-glutathionylation levels in total liver protein were detected by SDS-PAGE and Western blotting as previously described (Beer et al., 2004) were washed in PBS for 5 min at RT. All sections were examined by light microscopy (BX40, Olympus, Japan).
Statistical Analysis.
All statistical analyses were performed using SigmaPlot version 11.0 for Windows (Systat Software Inc., San Jose, CA). Data were analyzed by a one-way analysis of variance (ANOVA) followed by a Student-Neuman-Keuls post-hoc test. The level of significance was defined as the 0.05 level of probability. ALT and AST data were logtransformed before statistical analysis.
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RESULTS
Clinical and Histopathological Indices of APAP-Induced Liver Injury
A single oral gavage dose of 150 or 300 mg/kg APAP induced a dose-dependent increase in serum ALT and AST (Table 1) . Other clinical chemistry parameters were unaffected by APAP (data not shown). Increased ALT and AST values were observed as early as 1 hour after treatment at the higher 300 mg/kg APAP dose; whereas, statistically significant increases at 150 mg/kg were not observed until 6 and 24 hours after dosing (Table 1) .
Histopathological changes corroborated with the serum ALT and AST results.
Centrilobular hepatocellular degeneration was observed at 1 hour after dosing with centrilobular hepatocellular necrosis rimmed by degeneration occurring as early as 3 hours after dosing. Hepatocellular necrosis rimmed by degeneration surrounding central veins and often extending around sublobular/hepatic veins was observed at 6 and 24 hours after dosing with some high dose animals exhibiting marked necrosis at 24 hours.
APAP Treatment and the Oxidative State of the Liver
The high dose of APAP (300 mg/kg) induced a profound decrease in hepatic reduced glutathione (GSH) at 1 hour with levels starting to increase at 3 hours and recovery within 6 hours ( Figure 1 ). These results are consistent with those observed in previous studies (Adams et al., 1983; Smith and Jaeschke, 1989; Chen et al., 1990; Jaeschke, 1990; Srinivasan et al., 2001; Acharya and Lau-Cam, 2010 14 significantly altered for either treated group at 1 or 3 hours; however, by 6 hours, GSSG levels were significantly increased in the high dose group (Figure 1 ).
The absolute levels of GSH and GSSG give an indication of the oxidative state of the liver; however, another indicator that better portrays the oxidative balance is the ratio of GSH to GSSG. At 1 hour, the low dose had a ratio similar to controls; whereas, the high dose had a profound decrease in the GSH/GSSG ratio compared to controls (Figure 2 ), suggesting a more oxidative environment. At 3 and 6 hours, both the low and high dose groups had significantly decreased GSH/GSSG ratios, suggesting that both treatments created a more oxidative environment ( Figure 2 ).
Decreased Global Hepatic Protein Glutathionylation After APAP Exposure
Hepatic protein glutathionylation levels were measured by non-denaturing SDS-PAGE followed by Western blotting using a monoclonal anti-GSH antibody that recognizes glutathiolynated proteins. Control samples had a wide range of hepatic proteins that were glutathiolynated ( Figure 3A ). After APAP dosing, the level of global glutathionylation was slightly decreased compared to controls at the 1 and 3h timepoints (data not shown) but dramatically decreased, particularly in some individual samples, at the 6 and 24h timepoints ( Figures 3A and 4A ). Coomassie staining of separate polyacrylamide gels loaded with the same samples confirmed that protein loading was similar across all samples and that the decrease in glutathionylation was not an artifact of protein loading ( Figure 3B ). Regression analyses between overall glutathionylation level and histopathology score were conducted for the 6 and 24h timepoints. At 6h, decreased glutathionylation levels correlated with increasing severity of histopathological necrosis ( Figure 4B ). A similar trend was noted at 24h (data not shown). To confirm the specificity of the anti-GSH antibody for reversibly glutathiolynated proteins, liver homogenates were first reduced with dithiothreitol prior to SDS-PAGE to remove reversibly bound GSH. The reducing treatment essentially eliminated anti-GSH binding in these samples (data not shown).
Lobule Zonation of APAP Adducts in Relation to Protein Glutathionylation
Western blots provided useful information on the overall changes in glutathionylation, however, they could not be used to determine the pattern of glutathionylation changes within the hepatic lobule. This was important for a compound like APAP since it induces a specific centrilobular pattern of morphological effects and essentially spares the however, a mild increase in glutathionylation was observed throughout the central region hepatocytes ( Figure 6B ). This increase in glutathionylation correlated with the region of APAP adducts ( Figure 6C ). At 3 hours, clear morphological changes within the centrilobular hepatocytes were observed at the high dose of APAP and decreases in glutathionylation were observed within the most inner centrilobular hepatocytes (data not shown). This pattern was accentuated at 6 hours and, in addition, a rim of hepatocytes lying on the periphery of the centrilobular region exhibited increased levels of glutathionylation ( Figure 7B ). These same hepatocytes also had APAP adducts but appeared much less affected morphologically compared to the more inner centrilobular hepatocytes ( Figures 7A,C) . The low dose APAP animals exhibited similar changes in glutathionylation; however, the changes were delayed with regards to time and were not as dramatic as compared to the high dose (time course low dose data not shown). In contrast to the high dose of APAP, the low dose APAP livers still exhibited the rim pattern of increased glutathionylation at 24 hours ( Figure 8B ). The glutathionylation within the centrilobular regions, especially for the animals that had marked centrilobular necrosis ( Figure 8C , arrow heads), was dramatically decreased relative to the other regions of the lobule ( Figure 8D ). The rim pattern of increased glutathionylation was minimal at this timepoint in the high dose animals but could be observed around the less affected sublobule/hepatic veins ( Figure 8D , arrows).
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DISCUSSION
APAP overdose in mice produced classic signs of hepatotoxicity consisting of increased serum levels of ALT and AST, GSH depletion in the liver, and centrilobular necrosis.
Some of these effects were manifested as early as one hour after the dose highlighting the rapidity of APAP-induced cellular perturbation. In line with these effects, high levels of APAP adducts to protein were observed from 1 to 6 hours and were still present, albeit at lower levels, 24 hours after the high dose. All of these findings are consistent with previous reports of APAP-induced hepatotoxicity via the reactive metabolite NAPQI (Roberts et al., 1991; James et al., 2003) .
NAPQI is believed to induce cellular injury by binding cellular macromolecules and altering their structure or function. After NAPQI binds to a sufficient number of macromolecules, or specific macromolecules, key cellular processes are altered from which the cell cannot recover. However, NAPQI also dramatically alters the redox status of hepatocytes by depleting GSH, making hepatocytes more sensitive to oxidative stress. This is reflected by the depletion of protein thiols that is observed after APAP treatment (Albano et al., 1985; Kyle et al., 1990; Tirmenstein and Nelson, 1990) . Therefore, it is likely that protein structure and function are also indirectly affected by the severe depletion of GSH caused by NAPQI. This may be even more important than direct binding of NAPQI to macromolecules since the concentration of protein thiols oxidized after APAP has been shown to be over 10-fold greater than those directly conjugated by NAPQI (Tirmenstein and Nelson, 1990 ).
This article has not been copyedited and formatted. The final version may differ from this version. whereas, the ones with increased glutathionylation on the periphery had only subtle signs of injury at these timepoints. At 24 hours, glutathionylation in the high dose animals was dramatically decreased; whereas, the low dose animals still exhibited a rim pattern of increased glutathionylation. These time-and dose-dependent patterns of changes in protein glutathionylation are likely attributable to the differential distribution of CYP2E1 and the resulting toxicity response. Specifically, within the centrilobular area, CYP2E1 activity is high (Anundi et al., 1993) , and a large amount NAPQI is quickly produced, pool. However, in the cells around the centrilobular area, CYP2E1 activity is relatively low (Anundi et al., 1993) , thus NAPQI production is slower, and the increased cytosolic calcium level (Tirmenstein and Nelson, 1989) could stimulate mitochondrial oxidative phosphorylation, which helps maintain sufficient ATP levels to aid GSH bio-synthesis.
In addition, GSH synthesis enzymes could be induced by Nrf2 activation (Goldring et al., 2004) in these less-challenged cells after APAP exposure. Therefore, the GSH level is likely high enough to produce increased protein glutathionylation, which may help prevent the proteins from further irreversible damage or serve as a modulatory shown to have altered function after their glutathionylation status has been changed such as mitochondrial complexes I and II (Beer et al., 2004; Chen et al., 2007) . In addition, glutathionylation has been shown to play a role in the MPT. It was reported that carbon monoxide inhibited the MPT by glutathionylating adenine nucleotide translocase (ANT) and inhibiting its pore-forming function (Queiroga et al., 2010) . In the case of APAP, it is possible that decreased glutathionylation could lead to activation of the MPT through modification of pore-forming factors such as ANT. Since a large number of proteins exhibited decreased glutathionylation, it is a challenge to determine which modified protein(s), if any, has an actual toxicological consequence.
In conclusion, APAP decreased protein glutathionylation in mouse liver and even though GSH began to return to basal levels by 6 hours, protein glutathionylation remained depressed through 24 hours. The pattern of glutathionylation within the hepatic lobule indicated that hepatocytes that are not terminally damaged may increase glutathionylation levels to either protect proteins from irreversible damage or help them recover their native state. Hepatocytes closer to the central vein with terminal damage had dramatically decreased glutathionylation levels indicating that these cells were not able to maintain protein homeostasis. Given the dramatic decreases in hepatic GSH levels after APAP exposure, it is not surprising that protein glutathionylation also changes.
Additional research will help uncover whether the alterations are simply a passive mg/kg) was administered by oral gavage and hepatic GSH and GSSG levels were measured by UPLC/MS. APAP at 300 mg/kg produced a significant decrease in the GSH/GSSG ratio at 1 h, indicative of a more oxidizing environment within the liver. The GSH/GSSG ratio increased slightly within 6 h but was still significantly decreased compared to control levels. APAP at 150 mg/kg also decreased the GSH/GSSG ratio but the decrease was delayed and was lower in magnitude when compared to the 300 mg/kg group. * = GSH/GSSG ratio of 300 mg/kg group was statistically significantly decreased 
